BioSpace News Archive

Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announced financial results for the fourth quarter and full year 2020

Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2020.

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, reported financial results for the fourth quarter and full year ended December 31, 2020.

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it will host a conference call and provide a business update at 4:30 PM ET on Tuesday, March 2, 2021.

Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2020. Three-Month Periods Ended December 31, 2020 and 2019 Net service revenue increased $50.0 million to $550.7 million compared to $500.7 million in 2019. Net income attributable to Amedisys, Inc. of $45.2 million compared to $27.7 million in 2019.

Christopher Gerard named President and Chief Operating Officer and Scott Ginn named Executive Vice President and Chief Financial Officer

InflaRx N.V., a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced that it has commenced an underwritten public offering of common shares of the Company.

Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will be participating in the upcoming Cowen 41 st Annual Healthcare Conference. Seer’s management is scheduled to participate in a fireside chat on Wednesday, March 3 at 8:40 a.m. Pacific Time / 11:40 a.m. Eastern Time. A live webcast of the virtual session will be available on the Investor section of Seer’s

AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (“AVITA Medical”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today announced that it has commenced an underwritten registered public offering of its common stock

Antylia ScientificTM, a global leader in peristaltic and single use bioprocessing solutions, and a diverse portfolio of life sciences and diagnostic products for the pharma, biopharma, healthcare, and environmental markets